Alcohol Addiction (AA) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
ALCOHOL ADDICTION
• Alcohol addiction (AA) refers to psychological and physical dependency on alcohol. Alcohol dependence is considered a brain disease that shows alcohol-induced disturbances in brain structure, neurochemistry, and behavior. Symptoms are less involved in extracurricular activities, restlessness, depression, and inability to control drinking and violent behavior.
• Risk factors include age, family history, depression, and other mental health problems. Alcohol consumption will likely lead to other chronic diseases such as liver cirrhosis, epilepsy, poisoning, and several types of cancer.
• Treatment for alcohol dependence consists of behavioral therapy, which is generally provided alongside medicines. Abstinence and reduction goals are considered as part of a comprehensive treatment approach for alcohol dependence.
• Also, support from those close to the patient is very important. To overcome this issue, there are several customized addiction treatment centers that offer detoxification and rehabilitation programs. New drugs will also challenge the conventional wisdom around Alcohol addiction being the primary ? the often only solution to substance abuse.
• The U.S. Food and Drug Administration currently approved only three medications for the treatment of alcohol addiction.
• These medications are not prescribed to people who are still drinking alcohol. They are only given for those who already stopped drinking and are trying to maintain abstinence. Some of the current FDA approved drugs used in the treatment of alcoholism are Naltrexone (Vivitrol)– restricts the amount of the dopamine that creates in response to alcohol and helps to limit alcohol cravings, Acamprosate (Campral) – stabilizes chemical imbalances in the brains of patients and also helps in preventing relapse.
• It also reduces anxiety and mood swings and improves sleep, Antabuse (Disulfiram) – used as a deterrent to drinking because of the negative physical side effects when mixed with alcohol. Both Naltrexone and Acamprosate are antagonist therapies that work in the brain by binding to opiate receptors and work against the euphoric effects of addictive substances such as alcohol and heroin. Antabuse is considered as more aversion therapy.
• The alcohol addiction clinical pipeline consists of various drug molecules under different phases of drug development and shows that a higher number of studies is found to be in early phase, Phase I and Phase II trials compared to phase III trials.
• The drugs in the early phase, Phase I of drug development include PT150 by POPTest Oncology, Biological Fecal Microbial Transplant by OpenBiome and the drugs in Phase II trials include XR-NTX+HRC by Alkermes Inc, Behavioral RBIRT by Polaris Health Directions, PF-05190457, Doxazosin, Psilocybin, and Pioglitazone. Some of the drugs in Phase III trials of drug development include Acamprostate calcium, Topiramate, Naltrexone, Zonisamide, Nalmefene (Selincro), BACLOFEN, Memantine, Aripiprazole, and Intranasal Ketamine.
• The market is likely to be driven by the increasing government initiatives to augment the awareness level of consumers regarding alcohol addiction and deploying favorable reimbursement policies for AA therapy.
• The continual introduction of innovative therapies and drugs for addiction treatment is also expected to propel the market growth over the next few years.
• As the worldwide addiction treatment market future looks thriving, it may face several challenges in the years to come. The length of treatment procedures, which need time-to-time monitoring and multiple interventions, is projected to hamper the growth trajectory of this market over the forthcoming years
• Alcohol addiction (AA) refers to psychological and physical dependency on alcohol. Alcohol dependence is considered a brain disease that shows alcohol-induced disturbances in brain structure, neurochemistry, and behavior. Symptoms are less involved in extracurricular activities, restlessness, depression, and inability to control drinking and violent behavior.
• Risk factors include age, family history, depression, and other mental health problems. Alcohol consumption will likely lead to other chronic diseases such as liver cirrhosis, epilepsy, poisoning, and several types of cancer.
• Treatment for alcohol dependence consists of behavioral therapy, which is generally provided alongside medicines. Abstinence and reduction goals are considered as part of a comprehensive treatment approach for alcohol dependence.
• Also, support from those close to the patient is very important. To overcome this issue, there are several customized addiction treatment centers that offer detoxification and rehabilitation programs. New drugs will also challenge the conventional wisdom around Alcohol addiction being the primary ? the often only solution to substance abuse.
• The U.S. Food and Drug Administration currently approved only three medications for the treatment of alcohol addiction.
• These medications are not prescribed to people who are still drinking alcohol. They are only given for those who already stopped drinking and are trying to maintain abstinence. Some of the current FDA approved drugs used in the treatment of alcoholism are Naltrexone (Vivitrol)– restricts the amount of the dopamine that creates in response to alcohol and helps to limit alcohol cravings, Acamprosate (Campral) – stabilizes chemical imbalances in the brains of patients and also helps in preventing relapse.
• It also reduces anxiety and mood swings and improves sleep, Antabuse (Disulfiram) – used as a deterrent to drinking because of the negative physical side effects when mixed with alcohol. Both Naltrexone and Acamprosate are antagonist therapies that work in the brain by binding to opiate receptors and work against the euphoric effects of addictive substances such as alcohol and heroin. Antabuse is considered as more aversion therapy.
• The alcohol addiction clinical pipeline consists of various drug molecules under different phases of drug development and shows that a higher number of studies is found to be in early phase, Phase I and Phase II trials compared to phase III trials.
• The drugs in the early phase, Phase I of drug development include PT150 by POPTest Oncology, Biological Fecal Microbial Transplant by OpenBiome and the drugs in Phase II trials include XR-NTX+HRC by Alkermes Inc, Behavioral RBIRT by Polaris Health Directions, PF-05190457, Doxazosin, Psilocybin, and Pioglitazone. Some of the drugs in Phase III trials of drug development include Acamprostate calcium, Topiramate, Naltrexone, Zonisamide, Nalmefene (Selincro), BACLOFEN, Memantine, Aripiprazole, and Intranasal Ketamine.
• The market is likely to be driven by the increasing government initiatives to augment the awareness level of consumers regarding alcohol addiction and deploying favorable reimbursement policies for AA therapy.
• The continual introduction of innovative therapies and drugs for addiction treatment is also expected to propel the market growth over the next few years.
• As the worldwide addiction treatment market future looks thriving, it may face several challenges in the years to come. The length of treatment procedures, which need time-to-time monitoring and multiple interventions, is projected to hamper the growth trajectory of this market over the forthcoming years
